Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study.

OBJECTIVES: Netakimab is a humanised camelid-derived monoclonal antibody targeting interleukin-17A. Here, we report the results of post-hoc analysis of the ASTERA phase 3 study (NCT03447704, February 27, 2018) in patients with active radiographic axial spondyloarthritis (r-axSpA) grouped by baseline C-reactive protein (CRP), baseline sacroiliac joint (SIJ) inflammation through magnetic resonance imaging (MRI) or presence of peripheral arthritis (PA). METHODS: In this double-blinded, multicentre, randomised, placebo-controlled, phase 3 ASTERA study, 228 adult patients with active r-axSpA received 120 mg of subcutaneous netakimab or placebo at weeks 0, 1, 2, and thereafter every other week. For the subanalysis, 16-week data of 114 netakimab-treated patients with the available baseline CRP and SIJ MRI were grouped by normal (<5 mg/L) or abnormal (≥5 mg/L) CRP, by the grade of sacroiliitis (SI) based on the SPARCC MRI score <2 (MRI-SI-) or ≥2 (MRI-SI+), or by the presence of PA. ASAS-recommended activity, spinal mobility, and function endpoints for r-axSpA were analysed. RESULTS: At week 16, an improvement in all the outcomes was similar for MRI-SI- and MRI-SI+ patients, except for a change in ASspi-MRI-a which was significantly greater in MRI-SI+. Netakimab was effective regardless of baseline CRP and PA. For patients with CRP ≥5 mg/L, a more pronounced decline in r-axSpA activity was observed with a trend towards the most prominent improvement in ASDAS-CRP and BASDAI for patients with CRP >20 mg/L. CONCLUSIONS: Subcutaneous netakimab is effective in patients with r-axSpA irrespective of baseline CRP and inflammation on SIJ MRI. The benefit in patients with high CRP (>20 mg/L) was more pronounced.

Photoelectrochemical Behavior of Phthalocyanine-Sensitized TiO2 in the Presence of Electron-Shuttling Mediators.

Dye-sensitized TiO2 has found many applications for dye-sensitized solar cells (DSSC), solar-to-chemical energy conversion, water/air purification systems, and (electro)chemical sensors. We report an electrochemical system for testing dye-sensitized materials that can be utilized in photoelectrochemical (PEC) sensors and energy conversion. Unlike related systems, the reported system does not require a direct electron transfer from semiconductors to electrodes. Rather, it relies on electron shuttling by redox mediators. A range of model photocatalytic materials were prepared using three different TiO2 materials (P25, P90, and PC500) and three sterically hindered phthalocyanines (Pcs) with electron-rich tert-butyl substituents (t-Bu4PcZn, t-Bu4PcAlCl, and t-Bu4PcH2). The materials were compared with previously developed TiO2 modified by electron-deficient, also sterically hindered fluorinated phthalocyanine F64PcZn, a singlet oxygen (1O2) producer, as well as its metal-free derivative, F64PcH2. The PEC activity depended on the redox mediator, as well as the type of TiO2 and Pc. By comparing the responses of one-electron shuttles, such as K4Fe(CN)4, and 1O2-reactive electron shuttles, such as phenol, it is possible to reveal the action mechanism of the supported photosensitizers, while the overall activity can be assessed using hydroquinone. t-Bu4PcAlCl showed significantly lower blank responses and higher specific responses toward chlorophenols compared to t-Bu4PcZn due to the electron-withdrawing effect of the Al3+ metal center. The combination of reactivity insights and the need for only microgram amounts of sensing materials renders the reported system advantageous for practical applications.

Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.

OBJECTIVES: Netakimab (NTK) is a humanised monoclonal antibody targeting interleukin-17A, previously investigated in a phase 1 trial in healthy volunteers. Here, we report the results of a phase 2 trial, conducted to assess safety and pharmacokinetics (PK), to establish a therapeutic dose of NTK in a target population of patients with active ankylosing spondylitis (AS). METHODS: 89 patients with active AS, despite non-steroidal anti-inflammatory (NSAID) drug treatment, were randomised to receive 40, 80 or 120 mg of subcutaneous NTK or placebo at weeks 0, 1, 2 and q2wk thereafter until week 12. The primary endpoint was to achieve a proportion of patients with ≥20% improvement in Assessment of Spondyloarthritis. RESULTS: Rates of ASAS20 response at week 16 for NTK with 95%CI for difference in ASAS20 rates NTK vs. placebo were 72.73% [1.69%;58.05%], 81.82% [12.36%;65.56%], 90.91% [23.71%;72.39%] at doses of 40, 80 and 120 mg. The response rate in the placebo arm was 42.86%. The pre-specified margin of clinically non-meaningful difference was 10%. Superiority to placebo was confirmed for doses 80 and 120 mg. The most frequent adverse events (AEs) were lymphocytosis, neutropenia, and asymptomatic bacteriuria. No dose-dependent toxicity or serious adverse events (SAEs) were observed. The most effective dose with the fastest response onset and favourable safety profile was 120 mg. CONCLUSIONS: The data obtained demonstrate the efficacy and favourable safety profile of NTK in active AS. Clinical development of NTK will be continued in a phase 3 trial aimed to evaluate the efficacy of 1-year treatment with NTK 120 mg in patients with AS.

Sandwich double-decker Er(iii) and Yb(iii) complexes containing naphthalocyanine moiety: synthesis and investigation of the effect of a paramagnetic metal center.

Novel heteroleptic Er(iii) and Yb(iii) naphthalocyaninato-phthalocyaninates containing an octa-phenyl or octa-phenoxysubstituted naphthalocyanine deck were synthesised and identified by 1H NMR, EPR and high resolution MALDI-TOF/TOF mass spectrometry. Direct synthesis of novel homoleptic Yb(iii) bis (octa-phenylnaphthalocyaninate) was carried out. Downfield lanthanide induced shifts of the aromatic protons in target compounds were observed compared with the corresponding diamagnetic Lu(iii) complexes. In the near-IR absorption spectra, an increase in ionic radius from Lu(iii) to Er(iii) resulted in a bathochromic shift of the intervalence band up to 1473 nm. This work presents the first experimental EPR study of Yb(iii) bis naphthalocyaninate, where a set of magnetic parameters and properties (including spin, magnitude and sign of magnetic anisotropy parameter D, increased splitting in a crystal field, ferromagnetic f-π interaction etc.) were determined and interpreted by both EPR and SQUID techniques and supported by theoretical considerations.

Heteroleptic naphthalo-phthalocyaninates of lutetium: synthesis and spectral and conductivity properties.

Novel heteroleptic naphthalo-phthalocyaninates of lutetium possessing a symmetrical substituted naphthalocyanine deck were synthesized on the basis of two preformed synthetic blocks: naphthalocyanine ligand and lutetium phthalocyaninates. The compounds obtained were characterized by (1)H NMR and high-resolution MALDI-TOF/TOF mass spectrometry. The correlation between the nature of the substituents and the spectral properties of the target complexes was determined by the introduction of electron-donating (aryl-, aryloxy-) or electron-withdrawing (chloro-) substituents into the phthalocyanine deck. In addition, the nature of peripheral substituents was shown not to affect drastically the phthalocyanine conductivity and activation energy. Conductivity properties depend on thin film morphology which, in turn, relies on intermolecular π-π interactions.

Novel near-IR absorbing phenyl-substituted phthalo- and naphthalocyanine complexes of lanthanide(III): synthesis and spectral and electrochemical properties.

A series of novel phenyl-substituted planar and sandwich-type complexes of Eu, Er and Lu with phthalo and naphthalocyanine ligands was obtained. A successful synthesis of dinaphthalocyanines from the ligand is described. A selective synthetic approach to the phenyl-substituted triphthalocyanine complexes from the ligand and acetylacetonate salts of lanthanides was developed. Correlations between the ionic radii of the central metal and absorption maxima were obtained for sandwich-type complexes. It was found that intervalence (IV) bands for dinaphthalocyanine complexes were red-shifted about 200 nm in comparison with corresponding diphthalocyanines, reaching 1797 nm for the Eu complex. The electrochemical behaviour of planar and sandwich-type Lu complexes was investigated. For the first time a spectroelectrochemical study of multistep reduction and oxidation processes for a triple-decker complex was carried out using the example of the triphthalocyanine of Lu. The structures of the compounds obtained were determined by (1)H NMR and high resolution MALDI TOF/TOF. The first single-crystal structure for an aryl-substituted double-decker complex was described using the example of the diphthalocyanine of Lu, showing the presence of intramolecular π-π interactions between phenyl groups.